strong>Bristol-Myers Squibb Co., of New York, reported that primary endpoints were met in ALLY-1, a phase III trial evaluating a 12-week regimen of daclatasvir and Sovaldi (sofosbuvir, Gilead Sciences Inc.) once daily with ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) with either advanced cirrhosis or post-liver transplant recurrence of HCV.